Benjamin Cooper, MD
Plastic and Reconstructive Surgery · Wilmington, DENPI 1487650867
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $168, 3.3 times the $51 reported in 2019.
Across 27 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$158
- Avita Medical Americas, LLC$73
- Sientra, Inc.$72
- UCB, Inc.$71
- Avanos Medical$38
- Polynovo North America LLC$37
- plus $287 from 16 others
What the payments were for
- Travel & lodging$81%
- Food & beverage$72999%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 3 | $158 |
| Avita Medical Americas, LLC | 2 | $73 |
| Sientra, Inc. | 1 | $72 |
| UCB, Inc. | 1 | $71 |
| Avanos Medical | 1 | $38 |
| Polynovo North America LLC | 2 | $37 |
| Integra Lifesciences Corporation | 2 | $35 |
| Treace Medical Concepts, Inc. | 1 | $28 |
| Novocure Inc. | 1 | $25 |
| Triad Life Sciences Inc. | 1 | $20 |
| Vericel Corporation | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Bioventus LLC | 1 | $17 |
| Eclipse Technology Solutions Inc. | 1 | $16 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $16 |
| Fidia Pharma USA Inc. | 1 | $16 |
| Reapplix Inc. | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Solventum Corporation | 1 | $14 |
| KCI USA, Inc. | 1 | $13 |
| Lifenet Health | 1 | $12 |
| Kerecis Limited | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERSAJET II$125
How this compares
Too few plastic and reconstructive surgery providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gentamicin Sulfate | 39 | $1,133 |
| Mupirocin | 59 | $414 |
| Cephalexin | 39 | $371 |
| Doxycycline Hyclate | 41 | $247 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 26 | $106 |
| Oxycodone Hcl | 16 | $89 |
| Ciprofloxacin Hcl | 11 | $78 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in Wilmington
- Ian LonerganWilmington$364K
- Rhoda PowellWilmington$17
- John RoussalisNewark$13K
- Amir ArsalanNewark$3K
- Stephanie CatersonNewark$2K
- Jonathan SarikMilford$1K
- Jonathan SaundersNewark$237
- Julia MacraeNewark$226
- Mehdi BalakhaniNewark$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.